Skip to main content

Regeneron Pharmaceuticals Inc (REGN) Stock

Regeneron Pharmaceuticals Inc Stock Details, Movements and Public Alerts

Stock Details

Regeneron Pharmaceuticals Inc (REGN), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $752.62. Over the past 52 weeks, it has ranged between $475.17 and $790.98. This places the current price at 95.2% of its 52-week high and 58.4% above its 52-week low. Recent trading volume was recorded at 903,196. The 14-day Relative Strength Index (RSI) stands at 52.29, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $572.47 by 31.47%. Similarly, it is above its 200-day moving average of $605.71 by 24.25%. The MACD histogram is 1.27, indicating bullish momentum (MACD Line: 4.52, Signal Line: 3.25). The International Securities Identification Number (ISIN) for this stock is US75886F1075.

52-Week Range

$790.98 - $475.17

-4.85% from high · +58.39% from low

Avg Daily Volume

1,117,046

20-day average

100-day avg: 1,131,217

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

17.42

Near market average

Forward P/E

17.61

Earnings expected to decline

PEG Ratio

1.47

Reasonably valued

Price to Book

2.54

EV/EBITDA

12.74

EPS (TTM)

$42.87

Price to Sales

5.56

Beta

0.37

Less volatile than market

How is REGN valued relative to its earnings and growth?
Regeneron Pharmaceuticals Inc trades at a P/E ratio of 17.42, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 17.61 is higher than the current P/E, indicating analysts expect earnings to decline over the next year. The PEG ratio of 1.47 indicates reasonable value when growth is considered.
What is REGN's risk profile compared to the market?
With a beta of 0.37, Regeneron Pharmaceuticals Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 2.54 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

32.10%

Operating Margin

29.60%

EBITDA

$4.35B

Return on Equity

15.20%

Return on Assets

6.16%

Revenue Growth (YoY)

0.90%

Earnings Growth (YoY)

18.00%

How profitable and efficient is REGN's business model?
Regeneron Pharmaceuticals Inc achieves a profit margin of 32.10%, meaning it retains $32.10 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 29.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 15.20% and ROA at 6.16%, the company generates strong returns on invested capital.
What are REGN's recent growth trends?
Regeneron Pharmaceuticals Inc's revenue grew by 0.90% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 18.00% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Dividend Information

Dividend Per Share

$2.64

Dividend Yield

0.36%

Ex-Dividend Date

Nov 20, 2025

Dividend Date

Dec 5, 2025

What dividend income can investors expect from REGN?
Regeneron Pharmaceuticals Inc offers a dividend yield of 0.36%, paying $2.64 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of Nov 20, 2025.
How reliable is REGN's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Regeneron Pharmaceuticals Inc pays $2.64 per share in dividends against earnings of $42.87 per share, resulting in a payout ratio of 6.16%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for Dec 5, 2025.

Company Size & Market

Market Cap

$79.2B

Revenue (TTM)

$14.25B

Revenue/Share (TTM)

$134.76

Shares Outstanding

103.28M

Book Value/Share

$301.15

Asset Type

Common Stock

What is REGN's market capitalization and position?
Regeneron Pharmaceuticals Inc has a market capitalization of $79.2B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 103.28M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does REGN's price compare to its book value?
Regeneron Pharmaceuticals Inc's book value per share is $301.15, while the current stock price is $752.62, resulting in a price-to-book (P/B) ratio of 2.50. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$782.86

4.02% upside potential

Analyst Recommendations

Strong Buy

3

Buy

16

Hold

7

Sell

0

Strong Sell

1

How reliable are analyst predictions for REGN?
27 analysts cover REGN with 70% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $782.86 implies 4.0% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on REGN?
Current analyst recommendations:3 Strong Buy, 16 Buy, 7 Hold, 01 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Dec 13, 2025, 08:46 AM

Technical Indicators

RSI (14-day)

52.29

Neutral

50-Day Moving Average

$572.47

31.47% above MA-50

200-Day Moving Average

$605.71

24.25% above MA-200

MACD Line

4.52

MACD Signal

3.25

MACD Histogram

1.27

Bullish

What does REGN's RSI value tell investors?
The RSI (Relative Strength Index) for REGN is currently 52.29, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
How should traders interpret REGN's MACD and moving average crossovers?
MACD analysis shows the MACD line at 4.52 above the signal line at 3.25, with histogram at 1.27. This bullish crossover suggests upward momentum is building. The wide histogram confirms strong momentum. The 50-day MA ($572.47) is below the 200-day MA ($605.71), forming a death cross pattern that often warns of extended weakness. Price is currently above both MAs, confirming strength.

Indicators last updated: Oct 8, 2025, 12:54 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for REGN and get notified when the price changes.

Stay Ahead of the Market with Regeneron Pharmaceuticals Inc Alerts

Set up price alerts for Regeneron Pharmaceuticals Inc and get notified instantly when the price hits your target. Never miss an important price movement again.